Quviviq (daridorexant) is a prescription sleep medication approved by the FDA for treating insomnia in adults. It targets both difficulty falling asleep and trouble staying asleep through the night, making it useful for people who struggle with one or both of those problems.
How Quviviq Works
Your brain uses chemical messengers called orexins to keep you awake and alert. During the day, orexin activity is high, promoting wakefulness. At night, it naturally dials down so you can sleep. In people with insomnia, this system doesn’t quiet down the way it should.
Quviviq works by blocking both types of orexin receptors in the brain, reducing the signal that tells your body to stay awake. This is fundamentally different from older sleep medications like benzodiazepines or “Z-drugs” (such as zolpidem), which broadly suppress brain activity. Because Quviviq targets the wake-promotion system specifically rather than sedating the whole brain, it promotes sleep while preserving normal sleep architecture. That means you cycle through light sleep, deep sleep, and REM sleep more naturally.
One notable feature of this mechanism: the drug is most active when your orexin system is most active. If orexin levels are already low (as they are during restful sleep), the medication has less of an effect. This built-in ceiling helps explain why the side effect profile is relatively mild compared to older sedatives.
What Clinical Trials Show
The FDA approved Quviviq based on two large placebo-controlled trials. Both measured sleep in a lab using polysomnography, which tracks brain waves to precisely time when people fall asleep and how long they stay asleep.
At the 50 mg dose, people fell asleep about 11 to 12 minutes faster than those taking a placebo. They also spent 18 to 23 fewer minutes awake during the night. These improvements held steady over three months of use. The 25 mg dose showed smaller but still meaningful benefits: about 8 minutes faster to fall asleep and 10 to 12 fewer minutes of nighttime wakefulness compared to placebo.
Those numbers might sound modest on paper, but for someone lying awake at 3 a.m., shaving 20 minutes off nightly wake time adds up. And importantly, the benefits weren’t just about lab-measured sleep. Patients in the trials also reported improvements in how they felt during the day.
Effects on Daytime Functioning
A common frustration with insomnia is the daytime fallout: grogginess, trouble concentrating, irritability. The clinical trials measured this using a questionnaire that tracked daytime sleepiness, alertness, mood, and ability to function. In the pivotal trial, 50 mg of Quviviq produced a statistically significant reduction in daytime sleepiness compared to placebo within the first month. By three months, about 53% of people on the 50 mg dose reported a clinically meaningful improvement in daytime sleepiness, compared to 44% on placebo. More strikingly, 37% of people on the higher dose rated themselves “moderately better” or more on a global improvement scale, compared to 24% on placebo.
The 25 mg dose also improved daytime functioning, though the effects were smaller and not always statistically significant for sleepiness specifically. Self-reported sleep quality and daytime alertness improved at both doses.
Available Doses
Quviviq comes in two tablet strengths: 25 mg and 50 mg. The recommended dose is 25 mg or 50 mg taken once nightly. You take it within 30 minutes of going to bed, and only when you can get a full night of sleep. Eating a heavy or high-fat meal close to when you take it can delay the drug’s onset, so taking it on a lighter stomach works better.
Common Side Effects
The side effect profile in clinical trials was mild overall. Headache was the most frequently reported issue, affecting about 6% to 7% of people on Quviviq compared to 5% on placebo. Drowsiness or fatigue occurred in 5% to 6% (versus 4% on placebo), and dizziness in 2% to 3%. Nausea appeared in about 3% of people taking the 50 mg dose.
Rarer effects included sleep paralysis (a brief inability to move when waking up), which occurred in less than 1% of patients, and hallucinations at the boundary of sleep, also under 1%. Neither of these occurred in the placebo group, so they appear to be genuine drug effects, albeit uncommon ones. Both are related to the way the medication interacts with the sleep-wake transition and typically resolve quickly.
Controlled Substance Classification
Quviviq is classified as a Schedule IV controlled substance by the DEA, the same category as other commonly prescribed sleep aids. This classification reflects a low but real potential for misuse or dependence. In practice, Quviviq appears to carry less abuse potential than older sedative-hypnotics because it doesn’t produce the same kind of generalized sedation or euphoria. Still, the scheduling means prescriptions are tracked and refills are limited.
Who Should Not Take Quviviq
People with narcolepsy should not use Quviviq. Narcolepsy involves a deficiency of orexin, so blocking orexin receptors would worsen the condition. Alcohol and other central nervous system depressants can amplify Quviviq’s effects, increasing the risk of excessive sedation and impaired coordination. If you take medications that slow brain activity, such as certain anti-anxiety drugs, opioids, or other sleep aids, the combination requires careful evaluation.
Quviviq is approved only for adults. Its safety and effectiveness have not been established in children or adolescents.